{"id":3108,"date":"2015-10-23T06:30:00","date_gmt":"2015-10-23T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/"},"modified":"2015-10-23T06:30:00","modified_gmt":"2015-10-23T06:30:00","slug":"first-liver-transplant-with-steen-solution-performed-during-the-quarter","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/","title":{"rendered":"FIRST LIVER TRANSPLANT WITH STEEN SOLUTION\u2122 PERFORMED DURING THE QUARTER"},"content":{"rendered":"<\/p>\n

THIRD QUARTER 2015 (JUL \u2013 SEP)<\/span><\/p>\n<\/p>\n

\u00a0\u2022 Net sales in the quarter amounted to SEK 26.6 (22.4) million, corresponding to an increase of 19 percent.
\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 4.2 (3.4) million, corresponding to an EBITDA margin of 16 percent.
\u2022 Net income amounted to SEK 1.1 (1.5) million, resulting in earnings per share of SEK 0.05 (0.07). The figures are affected by amortization and depreciation of SEK 2.8 (1.2) million.
\u2022 Cash flow from operating activities was SEK 2.8 (4.3) million.
\u2022 Net sales of non-Durable goods* in the quarter amounted to SEK 24.3 (21.0) million, corresponding to an increase of 16 percent in SEK. Sales of non-Durable goods increased by 3 percent in local currency.
\u2022 Products for warm perfusion (STEEN Solution\u2122 and products related to the use of the XPS\u2122) accounted for 22 (25) percent of total sales of non-Durable goods. In total, products for warm perfusion and the XPS\u2122 accounted for 29 (30) percent of total sales.
\u2022 During the quarter rolling 12 month sales amounted to SEK 113 million. Rolling 12 month sales excluding capital goods amounted to SEK 102 million and were above SEK 100 million for the first time.
\u2022 The first clinical liver transplant with a liver perfused with STEEN Solution\u2122 was performed in Toronto, Canada. In total seven successful liver transplants have been performed as part of a phase 1 clinical trial.
\u2022 The company has taken a policy decision to apply for a listing on Nasdaq Stockholm\u2019s main list during 2016. This will entail one-time expenses for the company which will be recognized and reported on an ongoing basis during the coming year.<\/span><\/p>\n<\/p>\n

THE PERIOD 2015 (JAN \u2013 SEP)<\/span><\/p>\n<\/p>\n

\u00a0\u2022 Net sales in the period amounted to SEK 87.6 (59.2) million, corresponding to an increase of 48 percent.
\u2022 Operating income before depreciation and amortization (EBITDA) excluding one-time expenses amounted to SEK 11.3 (8.3) million, corresponding to an EBITDA margin of 13 percent.
\u2022 Net income amounted to SEK 1.4 (4.1) million, resulting in earnings per share of SEK 0.06 (0.20). The figures are affected by amortization and depreciation of SEK 8.5 (1.9) million.
\u2022 Cash flow from operating activities was SEK 5.7 (1.7) million.
\u2022 Net sales of non-Durable goods* in the period amounted to SEK 76.8 (57.7) million, corresponding to an increase of 33 percent in SEK. Sales of non-Durable goods increased by 15 percent in local currency.
\u2022 Products for warm perfusion (STEEN Solution\u2122 and products related to the use of the XPS\u2122) accounted for 29 (24) percent of total sales of non-Durable goods. In total, products for warm perfusion and the XPS\u2122 accounted for 38 (26) percent of total sales.<\/span><\/p>\n<\/p>\n

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER <\/span><\/p>\n<\/p>\n

\u2022 The AKH University Hospital in Vienna, Austria, which is the world\u2019s second largest lung transplant clinic, has decided to use the XPS\u2122. Delivery and installation of the XPS\u2122 took place in October.
\u2022 When the report was published 22 clinics have access to the XPS\u2122, of which 18 are located in the US.<\/span><\/p>\n<\/p>\n

CONFERENCE CALL<\/span><\/p>\n<\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, October 23, 2015. Telephone: +44 (0) 1452 555566, enter code 55238585.<\/span><\/p>\n<\/p>\n

October 23, 2015
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO<\/span><\/p>\n<\/p>\n

* Durable goods are sales revenues from the XPS\u2122.<\/span><\/p>\n

\n

For further information please contact:
<\/span>
Christoffer Rosenblad, CFO, 1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

The information was submitted for publication on\u00a0October 23, 2015\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

THIRD QUARTER 2015 (JUL \u2013 SEP) \u00a0\u2022 Net sales in the quarter amounted to SEK 26.6 (22.4) million, corresponding to…<\/p>\n","protected":false},"template":"","class_list":["post-3108","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q3"],"acf":[],"yoast_head":"\nFIRST LIVER TRANSPLANT WITH STEEN SOLUTION\u2122 PERFORMED DURING THE QUARTER - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FIRST LIVER TRANSPLANT WITH STEEN SOLUTION\u2122 PERFORMED DURING THE QUARTER - XVIVO\" \/>\n<meta property=\"og:description\" content=\"THIRD QUARTER 2015 (JUL \u2013 SEP) \u00a0\u2022 Net sales in the quarter amounted to SEK 26.6 (22.4) million, corresponding to...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\\\/\",\"name\":\"FIRST LIVER TRANSPLANT WITH STEEN SOLUTION\u2122 PERFORMED DURING THE QUARTER - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2015-10-23T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FIRST LIVER TRANSPLANT WITH STEEN SOLUTION\u2122 PERFORMED DURING THE QUARTER\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FIRST LIVER TRANSPLANT WITH STEEN SOLUTION\u2122 PERFORMED DURING THE QUARTER - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/","og_locale":"en_US","og_type":"article","og_title":"FIRST LIVER TRANSPLANT WITH STEEN SOLUTION\u2122 PERFORMED DURING THE QUARTER - XVIVO","og_description":"THIRD QUARTER 2015 (JUL \u2013 SEP) \u00a0\u2022 Net sales in the quarter amounted to SEK 26.6 (22.4) million, corresponding to...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/","name":"FIRST LIVER TRANSPLANT WITH STEEN SOLUTION\u2122 PERFORMED DURING THE QUARTER - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2015-10-23T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-liver-transplant-with-steen-solution-performed-during-the-quarter\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"FIRST LIVER TRANSPLANT WITH STEEN SOLUTION\u2122 PERFORMED DURING THE QUARTER"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}